[The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
We examined the effectiveness of naftopidil in 81 patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). We examined quality of life (QOL) and determined which symptoms improved as a result of naftopidil administration. The findings indicated that storage symptoms, voiding symptoms, total International Prostate Sympotom Score (IPSS), QOL index, Qmax and residual urine volume were significantly improved after treatment when compared to baseline. Improvement of nocturia and incomplete emptying by naftopidil contributed to improvement in QOL, odds ratio between the good response group and poor response group were 3.6 and 2.3, respectively. During naftopidil treatment, two of the 81 patients complained of adverse events. The results show that naftpidil is effective for LUTS caused by BPH, and that improvement of nocturia and incomplete emptying contributed to the improvement in QOL.
Nakatsu
Hiroomi
H
Department of Urology, Asahi General Hospital.
Naoi
Makito
M
Sekiyama
Kazuya
K
Hamano
Satoshi
S
Suzuki
Noriyuki
N
Tanaka
Masashi
M
Murakami
Shino
S
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D053158:Nocturia / Q000188:drug therapy / Q000503:physiopathology; D010879:Piperazines / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000523:psychology; D011788:Quality of Life; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil